HKSE · 2616.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:28 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
CStone Pharmaceuticals’s next earnings report is currently expected on Apr 1, 2027, with estimated earnings per share of -HK$0.14. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow CStone Pharmaceuticals’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Aug 23, 2024 |
| HK$0.01+110.0% vs estimate |
| HK$273.08M-17.73% vs estimate |
| Q4 2023 | Mar 27, 2024 | -HK$0.14-30.01% vs estimate | HK$222.63M-45.81% vs estimate |
|---|
| Q2 2023 | Aug 16, 2023 | -HK$0.18+41.38% vs estimate | HK$282.56M-26.51% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$437.80HK$0.00 (0.0%)
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 22.17% below the high.
HK$49.68-HK$0.24 (-0.48%)
Shanghai Henlius Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.96% below the high.
HK$17.55-HK$0.13 (-0.74%)
Zai Lab Limited’s quoted price sits in the upper half of its reported 52-week range, 18.07% below the high.
HK$21.12-HK$0.04 (-0.19%)
HUTCHMED (China) Limited’s quoted price sits in the upper half of its reported 52-week range, 17.44% below the high.
HK$11.46-HK$0.21 (-1.8%)
InnoCare Pharma Limited’s quoted price sits in the lower half of its reported 52-week range, 29.26% below the high.
HK$18.02-HK$0.58 (-3.12%)
Mabwell-b’s quoted price sits in the lower half of its reported 52-week range, 38.25% below the high.
HK$37.00+HK$0.02 (+0.05%)
Nanjing Leads Biolabs Co Ltd’s quoted price sits in the lower half of its reported 52-week range, 62.05% below the high.
HK$1.58HK$0.00 (0.0%)
Edding Genor Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 59.62% below the high.
